[go: up one dir, main page]

WO2005067940A1 - Nouvelle utilisation d'oligomere de glucane soluble dans l'eau isole depuis saccharomyces cerevisiae is2 afin de prevenir et de traiter la grippe aviaire - Google Patents

Nouvelle utilisation d'oligomere de glucane soluble dans l'eau isole depuis saccharomyces cerevisiae is2 afin de prevenir et de traiter la grippe aviaire Download PDF

Info

Publication number
WO2005067940A1
WO2005067940A1 PCT/KR2005/000168 KR2005000168W WO2005067940A1 WO 2005067940 A1 WO2005067940 A1 WO 2005067940A1 KR 2005000168 W KR2005000168 W KR 2005000168W WO 2005067940 A1 WO2005067940 A1 WO 2005067940A1
Authority
WO
WIPO (PCT)
Prior art keywords
gltcan
yeast
hrs
oligomer
soltble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2005/000168
Other languages
English (en)
Inventor
Won Kook Moon
Dong Woo Kim
Bong Hyun Chung
Jeong Hoon Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natural F and P Corp
Original Assignee
Natural F and P Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natural F and P Corp filed Critical Natural F and P Corp
Publication of WO2005067940A1 publication Critical patent/WO2005067940A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
    • A61H23/02—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
    • A61H23/0218—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with alternating magnetic fields producing a translating or oscillating movement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
    • A61H23/004—With mechanical drive, e.g. spring mechanism or vibrating unit being hit for starting vibration and then applied to the body of a patient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
    • A61H2201/12—Driving means
    • A61H2201/1207—Driving means with electric or magnetic drive

Definitions

  • the present invention relates to novel use of water soltble glt an oligomer isolated from Saccharomyces cerevisiae IS2 for the preparation of pharmaceutical composition to treat and prevent avian flu, specifically H1N2 type avian influenza in a mammal including htman in need thereof.
  • Background Art
  • avian flu including nonpathogenic and highly pathogenic flu are caused by avian viral infection mediated by poultries such as chick, duck, turkey, wild avian and the like on farms and in live markets.
  • highly pathogenic avian St influenza has been designated as the 1 group of legal communicable disease in Korea and List A infectious disease in OIE (Office International des Epizooties).
  • the pathogen, i.e., avian influenza virus, a sort of zoonotic virus is classified into highly pathogenic, weakly pathogenic and non-pathogenic virus according to their pathogenecity and there are 135 kinds of viruses according to their serotypes including 15 HA proteins and 9 NA proteins.
  • serotypes virulent avian virus transmitted to htman such as H5Nland H9N2 stbtype has been reported recently.
  • Avian influenza virus is frequently transmitted to htman through intermediate host such as swine, chicken, etc, modified by genetic nutation in the host and the mutated virus is transmitted to htman through respiratory tract and other pathway resulting in pathogenic avian flu.
  • H1N2 the stbtype of swine influenza virus isolated from Korean pig is H1N2 and the PA and PB gene isolated from 8 gene fragment of H1N2 isolated strain are derived from avian influenza virus (K. Jung and C. Chae., Archives of Virology, in press, 2004). Accordingly, it is confirmed that the H1N2 isolated strain has the part of avian influenza virus.
  • Beta-glucan can be isolated from various resources such as yeast, microorganism, mushroom, grain and algae. It has been studied and applied as various types of product till now. In particular, beta-glucan derived from yeast cell wall has been studied and known well.
  • Yeast a microorganism classified into GRAS (Generally Recognized As Safe) in FDA, has been used in various field including food field and the inner cell membrane of yeast comprises beta 1, 3- and 1, 6-gluccano as a main ingredients, and a small amount of chitin and mannoprotein, however, outer cell membrane thereof comprises mannoprotein, a protein linked to mannan.
  • Beta-glucan a major component of yeast cell wall has been reported to stirmlate immune system and reinforce the preventing mechanism of infected host by virus.
  • TNF- ⁇ secreted from macrophage and monocytes during inflammation and NO (inducible nitric oxide) induced therefrom are reported to be effective in preventing RNA virus including avian influenza virus (Akaike T et al, Immunology, 101. pp30 ⁇ 308, 200Q Seo S. H. et al, Journal of Virology, 76, ppl071-1076, 2002).
  • the inventors of the present invention have been endeavored to find pharmacologically potent beta-glucan from specific yeast variant strain from investigate and finally completed present invention by confirming that the soltble gltcan oligomer having less than 50,000 D of M. W. obtained by extracting the cell wall of yeast mutant IS2 shows potent anti-viral activity of swine influenza virus derived from avian influenza virus directly and indirectly.
  • the present invention provides a use of soltble gltcan oligomer derived from yeast variant strain IS2 (KCTC 0959BP) for the preparation of pharmaceutical composition to treat and prevent avian flu, specifically H1N2 type avian influenza in a mammal including htman in need thereof.
  • the present invention provides the pharmaceutical composition comprising soltble gltcan oligomer prepared by the method of the present invention for treating and preventing avian flu, specifically H1N2 type avian.
  • soltble gltcan oligomer derived from yeast variant strain IS2 KCTC 0959BP
  • avian flu specifically H1N2 type avian influenza in a mammal including htman in need thereof.
  • It is another object of the present invention to provide a pharmaceutical composition comprising soltble gltcan oligomer derived from yeast variant strain IS2 (K C T C 0959 B P ) for treating and preventing avian flu, specifically H 1 N2 type avian flu.
  • the soltble gltcan oligimer of the present invention may be prepared by the procedure comprising the steps consisting of: (a) culturing yeast ( Saccharomyces cerevisiae) variant IS2 (KCTC 0959BP) in the culture broth for inoculation; (b) inoculating above yeast culture solution to culture broth, culturing and centrifuging to obtain yeast; (c) adding NaOH thereto to extract beta-gltcan from yeast cell wall; (d) reacting extracted beta-gltcan with hydrolyzing enzyme and then stbjecting to filtration to obtain soltble gltcan oligomer; and (e) finally drying with lyophilization to obtain the soltble gltcan oligomer of the present invention.
  • yeast variant IS2 is characterized by treating and preventing avian flu.
  • the soltble gltcan oligomer prepared by above described procedure comprises gltcan oligomer having a molecular weight of less than 50,000, preferably, ranging from 1,000 to 10,000.
  • It is the other object of the present invention to provide a pharmaceutical composition comprising soltble gltcan oligomer derived from the cell wall of yeast variant strain (KTCT 0959BP) obtained by above described procedure as an active ingredient in an effective amount to treat and prevent avian flu, specifically H1N2 type avian flu, together with a pharmaceutically acceptable carrier thereof.
  • inventive soltble gltcan oligomer may be prepared in accordance with the following preferred e ⁇ i>odiment.
  • above described soltble gltcan oligomercan be prepared by following procedure;
  • yeast IS2 (KCTC 0959BP) consisting that yeast IS2 (KCTC 0959BP) is cultured in liquid culture median comprising 0.5 — 10 w/v% glucose, 0.1-5 w/v% yeast extract, 0.1-10 w/v% pepton;
  • [25] 2 step the step obtaining yeast from yeast culture median consisting that the yeast culture median prepared from the first stage in a amount ranging from 0.1 to 10% (v/v) is inoculated to primary liquid culture median comprising 0.5 — 10 w/v% glucose, 0.1-5 w/v% yeast extract, O ⁇ l-2 w/v% ammonian sulfate, 0fl01-l w/v% potassian phosphate, and 0fl01-l w/v% magnesian sulfate in the pH ranging from 5.0 to 6 ⁇ , cultured for the period ranging from 12 hours to 48 hours at the speed ranging from 100 to 400 rpm, in the ventilating gas amount ranging from 0.3 to 3 vvm, at the temperature ranging from 20 to 40 °C in growth media and then stbjected to cen- trifugation to obtain yeast;
  • [26] 3 r step the step extracting wet beta-gltcan from the cell wall of the yeast consisting that 1 — 10 % sodian hydroxide solution is added to the yeast, dispersed, reacted for the period ranging from 30 rrinutes to 5 hours at the temperature ranging from 70 to 100 °C, stbjected to centrifugation to obtain dried cell mass (DCW) of yeast, of which process may be repeated at several times to pool, titrating the pH of the mass ranging from 4 ⁇ to 5.0 using by strong acid such as hydrochloric acid and hydrogen sulfuric acid, dispersed again in sodian hydroxide solution, further reacting for 1 hour at 75 °C, stbjecting centrifugation to separate to sodian hydroxide solution and solid component; and finally washing and purifying the solid component to obtain wet beta- glucan;
  • DCW dried cell mass
  • [27] 4 step the step obtaining liquid phase of glucan oligomer consisting that distilled water at the amount equivalent to 1 to 10 times the volane of the gltcan (v/v%) and beta-gltcan hydrolyzing enzyme at the amount equivalent to 1/20 to 1/5 times of the glucan (v/w%) are added thereto, reacting for the period ranging from 6 to 24 hours at the temperature ranging from 30 to 80 °C, recovering supernatant solution by centrifuging after quenching the reaction, filtering supernatant with ultra filtration membrane to obtain inventive soltble gltcan oligomer solution having a molecular weight of less than 50,000.
  • [28] 5 step the step obtaining dried powder form of final soltble gltcan oligomer consisting that the oligomer prepared from 4 step is left alone for the period ranging from 12 hours to 48 hours at less than - 70 °C, and then stbject to lyophilzation to obtain the powder form of soltble gltcan oligomer of the present invention.
  • soltble gltcan oligomer derived from yeast variant IS2 (KCTC 0959BP) prepared by the preparation as described above and It is the other object of the present invention to provide a pharmaceutical composition comprising soltble gltcan oligomer derived from the cell wall of yeast variant strain (KTCT 0959BP) obtained by above described procedure as an active ingredient in an effective amount to treat and prevent avian flu, specifically H1N2 type avian flu, together with a pharmaceutically acceptable carrier thereof.
  • Above described avian flu comprises the flu caused by the infection of the avian influenza virus such as H1N2, H5N1, H9N2 stbtype influenza virus, preferably H1N2 stbtype virus.
  • the avian influenza virus such as H1N2, H5N1, H9N2 stbtype influenza virus, preferably H1N2 stbtype virus.
  • It is an object of the present invention to provide a use of a pharmaceutical composition comprising a soltble gltcan oligomer derived from yeast variant strain IS2 (KCTC 0959BP) for the preparation of therapeutic agent for treatment and prevention of avian flu in human or mammal in need thereof.
  • the inventive composition may additionally comprise conventional carrier, adjuvants or diluents in accordance with a using method. It is preferable that said carrier is used as appropriate stbstance according to the usage and application method, but it is not limited. Appropriate diluents are listed in the written text of Remington's Pharmaceutical Science (Mack Publishing co, Easton PA).
  • composition according to the present invention can be provided as a pharmaceutical composition containing pharmaceutically acceptable carriers, adjuvants or diluents, e.g., lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, acacia rtbber, alginate, gelatin, calcian phosphate, calcian silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesian stearate and mineral oil.
  • pharmaceutically acceptable carriers e.g., lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, acacia rtbber, alginate, gelatin, calcian
  • the forrmlations may additionally include fillers, anti-agglutinating agents, rubricating agents, wetting agents, flavoring agents, ermlsifiers, preservatives and the like.
  • the compositions of the invention may be forrmlated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a patient by employing any of the procedures well known in the art.
  • the composition of the present invention can be dissolved in oils, propylene glycol or other solvents which are commonly used to produce an injection.
  • suitable examples of the carriers include physiological saline, polyethylene glycol, ethanol, vegetable oils, isopropyl myristate, etc., but are not United to them.
  • the extract of the present invention can be forrmlated in the form of ointments and creams.
  • Pharmaceutical forrmlations containing crude drug composition may be prepared in any form, such as oral dosage form (powder, tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, powder, sachet, granule), or topical preparation (cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like), suppository, or sterile injectable preparation (solution, suspension, emulsion).
  • composition of the present invention in pharmaceutical dosage forms may be used in the form of their pharmaceutically acceptable salts, and also may be used alone or in appropriate association, as well as in coni ⁇ nation with other pharmaceutically active ingredients.
  • the desirable dose of the inventive composition varies depending on the condition and the weight of the stbject, severity, drug form, route and period of administration, and may be chosen by those skilled in the art. However, in order to obtain desirable effects, it is generally recommended to administer at the amount ranging 0.01-500 ⁇ g/kg, preferably, 0.1 to lOOmg/kg by weight/day of the inventive composition of the present invention.
  • the dose may be administered in a single or multiple doses per day.
  • the pharmaceutical composition for preventing and alleviating avian flu could contain about 0.1 to 50 w/w%, of the above soltble gltcan oligomer derived from yeast variant strain IS2 (KCTC 0959BP) of present invention based on the total weight of the composition.
  • composition of present invention can be administered to a stbject animal comprising mammals for example, rat, mouse, domestic animals such as dog, cat, cow, pig and htman via various routes. All modes of administration are contemplated well-known in the art, for example, administration can be made orally, rectally or by intravenous, intramuscular, stbcutaneous, intracutaneous, intrathecal, epidural or intracerebroventricular injection, or feeding by coni ⁇ ng with animal feed.
  • It is still another object of the present invention to provide a health care food comprising a composition essentially comprising a soltble gltcan oligomer derived from yeast variant strain IS2 (KCTC 0959BP), together with a sitologically acceptable additive for preventing and improving avian flu.
  • the health care food for preventing and alleviating avian flu could contain about 0.01 to 80 w/w%, preferably 1 to 50 w/w% of the above soltble gltcan oligomer derived from yeast variant strain IS2 (KCTC 0959BP) of present invention based on the total weight of the composition.
  • the present invention provides a composition of the health care food beverage for preventing and alleviating avian flu comprising a soltble gltcan oligomer derived from yeast variant strain IS2 (KCTC 0959BP).
  • Above inventive oligomer composition can be added to food and beverage for the preventing and alleviating avian flu.
  • examples of addable food comprising above oligomer composition of the present invention are e.g., various food, beverage, bread, cookies, jam, candy, gan, tea, yogurt, vitamin complex, health improving food and the like, and can be used as power, granule, tablet, chewing tablet, capsule or beverage etc.
  • composition of the present invention has no toxicity and adverse effect, therefore, they can be used with safe.
  • composition therein can be added to food, additive or beverage, wherein, the amount of above described oligomer in food or beverage may generally range from about 0.01 to 80 w/w % of total weight of food for the health care food composition and Offi to 30 g, preferably 0.3 to 5 g in the ratio of 100m ⁇ of the health beverage composition.
  • the health beverage composition of present invention contains above described oligomer as an essential component in the indicated ratio
  • the other component can be various deodorant or natural carbohydrate etc such as conventional beverage.
  • natural carbohydrate are rronosaccharide such as glucose, fructose etc; disaccharide such as maltose, sucrose etc; conventional sugar such as dextrin, cyclodextrin; and sugar alcohol such as xylitol, and erythritol etc.
  • natural deodorant such as taanatin, stevia extract such as levaudioside A, glycyrrhizin et al., and synthetic deodorant such as saccharin, aspartam et al.
  • the amount of above described natural carbohydrate is generally ranges from about 1 to 20 g, preferably 5 to 12 g in the ratio of 100 M of present beverage composition.
  • the other components than aforementioned composition are various nutrients, a vita ⁇ in, a mineral or an electrolyte, synthetic flavoring agent, a coloring agent and improving agent in case of cheese chocolate et al., pectic acid and the salt thereof, alginic acid and the salt thereof, organic acid, protective colloidal adhesive, pH controlling agent, stabilizer, a preservative, glycerin, alcohol, carbonizing agent used in carbonate beverage et al.
  • the other component than aforementioned ones may be fruit juice for preparing natural fruit juice, fruit juice beverage and vegetable beverage.
  • the inventive composition can be used as the mixing agent in the lactic acid bacteria-formilated beverage or paste and the like.
  • the present invention provides a health care food comprising about O ⁇ l to 30 w/w % of the vita ⁇ in, oligosaccharides and dietary ingredients besides the composition of the present invention.
  • the ratio of the components is not so important but is generally ranging from about 0.01 to 30 w/w % per 100 w/w % present composition.
  • addable food comprising aforementioned extract therein are various food, beverage, gan, vitamin complex, health improving food and the like.
  • the inventive composition may additionally comprise one or more than one of organic acid, such as citric acid, fanaric acid, adipic acid, lactic acid, malic acid; phosphate, such as phosphate, sodian phosphate, potassian phosphate, acid py- rophosphate, polyphosphate; natural anti-oxidants, such as polyphenol, catechin, ⁇ - tocopherol, rosemary extract, vitamin C, licorice root extract, chitosan, tannic acid, phytic acid etc.
  • organic acid such as citric acid, fanaric acid, adipic acid, lactic acid, malic acid
  • phosphate such as phosphate, sodian phosphate, potassian phosphate, acid py- rophosphate, polyphosphate
  • natural anti-oxidants such as polyphenol, catechin, ⁇ - tocopherol, rosemary extract, vitamin C, licorice root extract, chitosan, tannic acid, phytic acid etc.
  • soltble gltcan oligomer having less than 50,000 D of M.W. prepared by treating insoltble beta-gltcan isolated the cell wall of yeast variant IS2 with commercially available beta-gltcan hydrolyzing enzymes showed potent anti-viral activity of swine influenza virus derived from avian influenza virus directly and indirectly, therefore, it can be used as the therapeutics or health care food for treating and preventing avian flu.
  • Fig. 1 shows the effect of soltble gltcan oligomer on NO production by mouse lymphocytes after peritoneal injection
  • Fig. 2 shows the effect of soltble gltcan oligomer on 11 ⁇ 2 production in spleen cell when it peritoneally injected to mouse
  • the present invention is more specifically explained by the following examples. However, it should be understood that the present invention is not United to these examples in any manner. Mode for the Invention
  • the following Examples and Experimental Examples are intended to further illustrate the present invention without Uniting its scope.
  • Example 1 Culture of yeast variant IS2 and harvest
  • Liquid YPD median (glucose 20 g/1, yeast extract 10 g/1, peptone 20 g/1) was used for inoculation and growth media containing 400g/l of glucose, 30 g/1 yeast extract, 40 g/1 of ammonian sulfate ((NH ) SO ), 15 g/1 of potassian phosphate (K PO ) and 5.7 4 2 4 2 4 g/1 of magnesian sulfate (MgSO • 7H O). 4 2
  • the separated solid part was suspended again in 2000 ⁇ of 3 % sodian hydroxide solution, inctbated at 75 °C for 3 hours and then centrifuged at the speed of 2000 rpm for 15 rrinutes to separate into NaOH solution and solid part again.
  • the pooled solid part was adjusted to pH 4.5 with HC1, dispersed to the extent the final volume of 2000 M and inctbated at 75 °C for 1 hour again.
  • the inctbated suspension was centrifuged at the speed of 2000 rpm for 15 minutes to separate into NaOH solution part and solid part.
  • the reaction mixture was centrifuged at 7000 rpm for 15 minutes to collect the supernatant.
  • the collected supernatant was filtered and the un- reacted enzymes were removed using by ultra filtration membrane (Filtron Go., MWCO 10K) to obtain the solution containing gltcan oligomer having MW of less than 10,000 Dalton.
  • the solution was lyophilized to produce 5.8 g of powder form of soltble gltcan oligomer.
  • test group containing soltble gltcan oligomer prepared from Example 3 and control group on the production of NO (Nitric Oxide) and TNF- ⁇ secreted from alveolar macrophage caused by LPS (Upopolysacchande) treatment was determined by following experiment.
  • porcine virus i.e., porcine parvovirus, porcine circovirus type 2, porcine circovirus type 1, porcine reproductive and respiratory syndrome virus, Japanese encephalitis virus, encephalomye- locarditis virus and pseudorabies virus or not
  • PCR polymerase chain reaction
  • test groups injected with soltble gltcan oligomer showed about 4 to 5 folds of increased NO production in alveolar macrophage compared with that of negative control ( See Fig. 1).
  • TNF- ⁇ As the result of determination of TNF- ⁇ production, the expression of TNF- ⁇ has been increased from 12 hrs to 48 hrs after the inoculation and sharply decreased at 60 hr after the inoculation in virus treatment group.
  • the expressed amount of TNF- ⁇ in test group treated with water soltble gltcan oligomer was significantly higher than that of negative control for the period ranging from 24 to 60 hours after the inoculation ( See Fig. 2, P ⁇ 0D5).
  • Indirect antiviral activity of test sample group and negative control group was determined by treating the supernatants of the culture median in alveolar macrophage with virus and inoculating into culture cell to observe the cytopathic effect caused by influenza virus.
  • Direct antiviral activity of test sample group and negative control group was determined by treating sample with influenza virus directly.
  • H1N2 isolation strain was used as a swine influenza virus and the TCID value was 5x 10 75 /ml.
  • Mono-layer cell was cultured and grown in 96 well plates. 5mg/ml of the gltcan oligomer (GO group) and gltcan LPS (GL group) treated supernatant were used as NO treatment groups. As a negative control group, DMEM culture median and gltcan/ LPS non-treated supernatant was used in the experiment. The viruses were inoculated 3 2 in various concentrations, i.e., 10 , 10 , 10 TCID /well.
  • the CPE caused by inoculated viruses was determined by inverted microscope and the results were classified into four grades, i.e., +++(strongest CPE), ++ (moderate CPE), + (rrild CPE), and - (no CPE) according to the method disclosed in the literature (Belaid et al., J. Me ⁇ . Virol, 66(2). pp229-34, 2002). Serial three wells were used as each group and the mean of resulting values was determined.
  • the most abundant virus treatment group (10 TCID ) showed higher 50 inhibiting activity by about 70% and 30% of CPE caused by porcine influenza virus compared with that of control group at 24 hours and 36 hours after the inoculation re- 2 1 spectively.
  • the least abundant virus treatment group (10 and 10 TCID ) 50 showed most potent inhibiting activity by about 100% of CPE caused by porcine influenza virus compared with that of control group at 36 hours after the inoculation
  • the CPE caused by inoculated viruses was determined by inverted microscope and the results were classified into four grades, i.e., +++(strongest CPE), ++ (moderate CPE), + (rrild CPE), and - (no CPE) according to the method disclosed in the literature (Belaid et al., J. Me ⁇ . Virol, 66(2 . pp229-34, 2002). Serial three wells were used as each group and the mean of resulting values was determined.
  • the group treated with only gltcan oligomer showed 100% antiviral activity regardless of the amount of virus compared with control group till 24 hours. 36 hours after the inoculation, the most abundant virus 3 treatment group (10 TCID ) showed 70% of antiviral activity and the least abundant 2 5 ° 1 virus treatment group (10 and 10 TCID ) showed 100% of antiviral activity. 50
  • Powder preparation was prepared by nixing above components and filUng sealed package.
  • Tablet preparation was prepared by nixing above components and filling gelatin capsule by conventional gelatin preparation method.
  • Injection preparation was prepared by dissolving active component, controlling pH to about 7.5 and then filling all the components in 2 M ample and sterilizing by conventional injection preparation method.
  • Liquid preparation was prepared by dissolving active component, filling all the components and sterilizing by conventional liquid preparation method.
  • Health beverage preparation was prepared by dissolving active component, nixing, stirred at 85°C for 1 hour, filtered and then filling all the components in 1000m ⁇ ample and sterilizing by conventional health beverage preparation method.
  • soltble gltcan oligomer having a M.W. ranging from l ⁇ OO to 10,000 prepared by treating insoltble beta-gltcan isolated the cell wall of yeast variant IS2 with commercially available beta-gltcan hydrolyzing enzymes showed potent anti-viral activity of swine influenza virus derived from avian influenza virus directly and indirectly, therefore, it can be used as the therapeutics or health care food for treating and preventing avian flu.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Rehabilitation Therapy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une nouvelle utilisation d'un oligomère de glucane soluble dans l'eau possédant un M.W. entre 1000 et 10000 et préparé par traitement d'un bêta-glucane insoluble isolé de la variante IS2 de la levure de paroi cellulaire avec des enzymes d'hydrolyse de bêta-glucane vendus dans le commerce afin de préparer une composition pharmaceutique servant à traiter et à prévenir la grippe aviaire chez un mammifère y compris l'humain. Cet oligomère peut être, par conséquent, utilisé en tant qu'aliment thérapeutique ou hygiénique pour traiter ou prévenir la grippe aviaire.
PCT/KR2005/000168 2004-01-19 2005-01-19 Nouvelle utilisation d'oligomere de glucane soluble dans l'eau isole depuis saccharomyces cerevisiae is2 afin de prevenir et de traiter la grippe aviaire Ceased WO2005067940A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020040003621A KR100485056B1 (ko) 2004-01-19 2004-01-19 효모의 수용성 글루칸 올리고머를 함유하는 항 h1n2형 조류독감 바이러스제
KR10-2004-0003621 2004-01-19

Publications (1)

Publication Number Publication Date
WO2005067940A1 true WO2005067940A1 (fr) 2005-07-28

Family

ID=34793278

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2005/000168 Ceased WO2005067940A1 (fr) 2004-01-19 2005-01-19 Nouvelle utilisation d'oligomere de glucane soluble dans l'eau isole depuis saccharomyces cerevisiae is2 afin de prevenir et de traiter la grippe aviaire

Country Status (3)

Country Link
KR (1) KR100485056B1 (fr)
CN (1) CN1909914A (fr)
WO (1) WO2005067940A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006046960A1 (de) * 2006-10-04 2008-04-10 Euro Allianz Pharma Gmbh Gesundheitsfördernde Nahrungsmittelzusammensetzung
CN101117357B (zh) * 2007-09-17 2010-06-02 中国农业大学 一种水溶性β-1,3/1,6-葡聚糖的制备方法
US20100189827A1 (en) * 2006-06-29 2010-07-29 Rnl Bio Co., Ltd. Antiviral composition comprising alnus japonica extracts
WO2023046844A1 (fr) * 2021-09-27 2023-03-30 Biocodex Compositions pharmaceutiques utiles pour la prévention ou le traitement d'infections virales

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101880635B (zh) * 2010-05-24 2012-05-23 中国农业科学院农产品加工研究所 高β-葡聚糖含量的酿酒酵母突变菌株及其应用
CN108611385A (zh) * 2016-12-12 2018-10-02 安琪酵母股份有限公司 水溶性酵母β-葡聚糖及其制备方法和应用
CN107232610A (zh) * 2017-05-25 2017-10-10 杭州特悘衡康生物科技有限公司 一种含酵母β‑葡聚糖的碳水化合物组合物及其应用
CO2020004754A1 (es) 2020-04-17 2020-10-20 Compania Nac De Levaduras Levapan S A Proceso de obtención de β-glucano a partir de levadura de panadería

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987001037A1 (fr) * 1985-08-19 1987-02-26 The Administrators Of The Tulane Educational Fund Glucane soluble phosphoryle
US5783569A (en) * 1992-08-21 1998-07-21 Alpha-Beta Technology, Inc. Uses for underivatized, aqueous soluble β(1-3) glucan and compositions comprising same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975421A (en) * 1985-08-19 1990-12-04 Bioglucan, Lp. Soluble phosphorylated glucan: methods and compositions for wound healing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987001037A1 (fr) * 1985-08-19 1987-02-26 The Administrators Of The Tulane Educational Fund Glucane soluble phosphoryle
US5783569A (en) * 1992-08-21 1998-07-21 Alpha-Beta Technology, Inc. Uses for underivatized, aqueous soluble β(1-3) glucan and compositions comprising same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AKESENOV ET AL.: "Polysaccharide biological activity dependent on structural characteristics.", IN ANTIBIOTIKI., vol. 21, no. 22, 1976, pages 974 - 979 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100189827A1 (en) * 2006-06-29 2010-07-29 Rnl Bio Co., Ltd. Antiviral composition comprising alnus japonica extracts
DE102006046960A1 (de) * 2006-10-04 2008-04-10 Euro Allianz Pharma Gmbh Gesundheitsfördernde Nahrungsmittelzusammensetzung
CN101117357B (zh) * 2007-09-17 2010-06-02 中国农业大学 一种水溶性β-1,3/1,6-葡聚糖的制备方法
WO2023046844A1 (fr) * 2021-09-27 2023-03-30 Biocodex Compositions pharmaceutiques utiles pour la prévention ou le traitement d'infections virales

Also Published As

Publication number Publication date
KR100485056B1 (ko) 2005-04-22
CN1909914A (zh) 2007-02-07

Similar Documents

Publication Publication Date Title
EP3141254B1 (fr) Lactobacillus rhamnosus rht-3201 conjugue a un liant polymere polysaccharide, et son utilisation pour la prevention ou le traitement de maladies atopiques
TWI787950B (zh) 用於預防、緩解或治療冠狀病毒感染的包括杜英萃取物作為活性成分之藥物組成物以及食品組成物
KR101886337B1 (ko) 락토바실러스 플란타륨 dsr m2를 유효성분으로 함유하는 인플루엔자 바이러스에 대한 항바이러스용 조성물
WO2005067940A1 (fr) Nouvelle utilisation d'oligomere de glucane soluble dans l'eau isole depuis saccharomyces cerevisiae is2 afin de prevenir et de traiter la grippe aviaire
KR101271601B1 (ko) 인플루엔자 바이러스 유래 질병의 예방 또는 치료용 조성물
KR101160743B1 (ko) 녹차를 유효성분으로 함유하는 조류 인플루엔자에 대한 항바이러스제
KR101501876B1 (ko) 자일리톨을 유효성분으로 함유하는 인플루엔자 바이러스 감염증 예방 또는 치료용 조성물
CN100463680C (zh) 抑制猪流感(siv)和可传播的肠胃炎冠状病毒(tgev)的含有来自酿酒酵母is2的可溶性葡聚糖低聚物的组合物
US20060178340A1 (en) Composition comprising soluble glucan oligomer from saccharomyces cerevisiae is2 for immune activation or prevention and treatment of cancer and the preparation method thereof
TWI496578B (zh) 流感病毒感染症的治療劑
KR101119538B1 (ko) 시알릭산-함유 유청 단백질을 유효성분으로 함유하는 인플루엔자 바이러스 감염증의 예방 및 치료용 조성물
JP5372547B2 (ja) 免疫グロブリンａ産生促進剤
TWI757735B (zh) 乳酸菌用於製備抗病毒組合物的用途
KR102237450B1 (ko) 강황잎 추출물을 유효성분으로 포함하는 장기능 개선용 조성물
KR102143608B1 (ko) 락토바실러스 사케이 k040706을 함유하는 바이러스 감염 질환 예방 또는 치료용 조성물
KR20210003614A (ko) 감잎 유래 다당 분획물을 유효성분으로 함유하는 인플루엔자 바이러스 감염 질환의 개선, 예방 또는 치료용 조성물
US20240148778A1 (en) Glycoside inhibitors of yeast
JP2010132630A (ja) 抗インフルエンザウイルス組成物及びインフルエンザ予防食品
KR102604953B1 (ko) 발효 더덕의 제조방법, 발효 더덕 및 이를 포함하는 항바이러스용 조성물
KR102210919B1 (ko) 보리잎 유래 다당 분획물을 유효성분으로 함유하는 인플루엔자 바이러스 감염 질환의 개선, 예방 또는 치료용 조성물
KR20190071469A (ko) 류코노스톡 메센테로이드 dsr 218을 유효성분으로 함유하는 인플루엔자 바이러스에 대한 항바이러스용 조성물
RU2780346C1 (ru) Терапевтический агент против коронавируса, включающий экстракт elaeocarpus sylvestris
KR20110057011A (ko) 인플루엔자 바이러스 감염의 예방 및 치료용 조성물 및 뉴라미니데이즈 활성의 억제용 조성물
KR20240155667A (ko) 갯잔디 추출물을 유효성분으로 포함하는 항바이러스용 조성물
KR20210145929A (ko) 항바이러스 활성을 지닌 건강기능식품의 제조방법

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200580002741.2

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase